Breaking News
16 hours ago
Simantini Singh Deo

AbbVie's nine-year CLL14 data show 7.6-year median time to next treatment, reshaping venetoclax supply and lifecycle planning.
Simantini Singh Deo

KIHT receives government approval to operate as a CRO for drugs and medical devices, expanding India's clinical research capacity.
Simantini Singh Deo

IPC's IP 2026 conclave signals tightening compliance timelines for manufacturers in and exporting to India.
Simantini Singh Deo

ASSOCHAM projects India's pharma market at US$130B and exports at US$80B by 2030, with biosimilars, biologics, and regulatory harmonization as key drivers.
Simantini Singh Deo
